Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients

Francesca Galardi, Catherine Oakman, Maria Caterina Truglia, Silvia Cappadona, Annibale Biggeri, Laura Grisotto, Lisa Giovannelli, Silvia Bessi, Augusto Giannini, Laura Biganzoli, Libero Santarpia, Angelo Di Leo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

There are no clinical tools to functionally assess degree of DNA damage in breast cancer. The comet assay is an accepted research tool for assessing DNA damage, however, most cancer studies have assessed lymphocytes as surrogate cells. The aim of this pilot study was to use the comet assay in early breast cancer directly in tumor tissue to compare DNA damage between and within traditionally defined subgroups, and to explore intra-tumoral heterogeneity. Scrapings of tumor and healthy breast tissue were obtained at primary surgery from 104 women. Comet assay was applied to quantitatively assess DNA damage, revealing substantial inter- and intra-subgroup variation. Marked intra-tumoral heterogeneity was evident across all subgroups. The degree of DNA damage for an individual could not be predicted by breast cancer subgroup. Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy.

Original languageEnglish
Pages (from-to)336-342
Number of pages7
JournalBreast
Volume21
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Comet Assay
DNA Damage
Breast Neoplasms
Genetic Therapy
Neoplasms
Lymphocytes
Research

Keywords

  • Breast cancer
  • Comet assay
  • DNA damage
  • Single cell gel electrophoresis

ASJC Scopus subject areas

  • Surgery

Cite this

Galardi, F., Oakman, C., Truglia, M. C., Cappadona, S., Biggeri, A., Grisotto, L., ... Di Leo, A. (2012). Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast, 21(3), 336-342. https://doi.org/10.1016/j.breast.2012.02.007

Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. / Galardi, Francesca; Oakman, Catherine; Truglia, Maria Caterina; Cappadona, Silvia; Biggeri, Annibale; Grisotto, Laura; Giovannelli, Lisa; Bessi, Silvia; Giannini, Augusto; Biganzoli, Laura; Santarpia, Libero; Di Leo, Angelo.

In: Breast, Vol. 21, No. 3, 06.2012, p. 336-342.

Research output: Contribution to journalArticle

Galardi, F, Oakman, C, Truglia, MC, Cappadona, S, Biggeri, A, Grisotto, L, Giovannelli, L, Bessi, S, Giannini, A, Biganzoli, L, Santarpia, L & Di Leo, A 2012, 'Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients', Breast, vol. 21, no. 3, pp. 336-342. https://doi.org/10.1016/j.breast.2012.02.007
Galardi, Francesca ; Oakman, Catherine ; Truglia, Maria Caterina ; Cappadona, Silvia ; Biggeri, Annibale ; Grisotto, Laura ; Giovannelli, Lisa ; Bessi, Silvia ; Giannini, Augusto ; Biganzoli, Laura ; Santarpia, Libero ; Di Leo, Angelo. / Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. In: Breast. 2012 ; Vol. 21, No. 3. pp. 336-342.
@article{3aaf223812b3446794d65776524979b9,
title = "Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients",
abstract = "There are no clinical tools to functionally assess degree of DNA damage in breast cancer. The comet assay is an accepted research tool for assessing DNA damage, however, most cancer studies have assessed lymphocytes as surrogate cells. The aim of this pilot study was to use the comet assay in early breast cancer directly in tumor tissue to compare DNA damage between and within traditionally defined subgroups, and to explore intra-tumoral heterogeneity. Scrapings of tumor and healthy breast tissue were obtained at primary surgery from 104 women. Comet assay was applied to quantitatively assess DNA damage, revealing substantial inter- and intra-subgroup variation. Marked intra-tumoral heterogeneity was evident across all subgroups. The degree of DNA damage for an individual could not be predicted by breast cancer subgroup. Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy.",
keywords = "Breast cancer, Comet assay, DNA damage, Single cell gel electrophoresis",
author = "Francesca Galardi and Catherine Oakman and Truglia, {Maria Caterina} and Silvia Cappadona and Annibale Biggeri and Laura Grisotto and Lisa Giovannelli and Silvia Bessi and Augusto Giannini and Laura Biganzoli and Libero Santarpia and {Di Leo}, Angelo",
year = "2012",
month = "6",
doi = "10.1016/j.breast.2012.02.007",
language = "English",
volume = "21",
pages = "336--342",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients

AU - Galardi, Francesca

AU - Oakman, Catherine

AU - Truglia, Maria Caterina

AU - Cappadona, Silvia

AU - Biggeri, Annibale

AU - Grisotto, Laura

AU - Giovannelli, Lisa

AU - Bessi, Silvia

AU - Giannini, Augusto

AU - Biganzoli, Laura

AU - Santarpia, Libero

AU - Di Leo, Angelo

PY - 2012/6

Y1 - 2012/6

N2 - There are no clinical tools to functionally assess degree of DNA damage in breast cancer. The comet assay is an accepted research tool for assessing DNA damage, however, most cancer studies have assessed lymphocytes as surrogate cells. The aim of this pilot study was to use the comet assay in early breast cancer directly in tumor tissue to compare DNA damage between and within traditionally defined subgroups, and to explore intra-tumoral heterogeneity. Scrapings of tumor and healthy breast tissue were obtained at primary surgery from 104 women. Comet assay was applied to quantitatively assess DNA damage, revealing substantial inter- and intra-subgroup variation. Marked intra-tumoral heterogeneity was evident across all subgroups. The degree of DNA damage for an individual could not be predicted by breast cancer subgroup. Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy.

AB - There are no clinical tools to functionally assess degree of DNA damage in breast cancer. The comet assay is an accepted research tool for assessing DNA damage, however, most cancer studies have assessed lymphocytes as surrogate cells. The aim of this pilot study was to use the comet assay in early breast cancer directly in tumor tissue to compare DNA damage between and within traditionally defined subgroups, and to explore intra-tumoral heterogeneity. Scrapings of tumor and healthy breast tissue were obtained at primary surgery from 104 women. Comet assay was applied to quantitatively assess DNA damage, revealing substantial inter- and intra-subgroup variation. Marked intra-tumoral heterogeneity was evident across all subgroups. The degree of DNA damage for an individual could not be predicted by breast cancer subgroup. Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy.

KW - Breast cancer

KW - Comet assay

KW - DNA damage

KW - Single cell gel electrophoresis

UR - http://www.scopus.com/inward/record.url?scp=84862513854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862513854&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2012.02.007

DO - 10.1016/j.breast.2012.02.007

M3 - Article

C2 - 22406214

AN - SCOPUS:84862513854

VL - 21

SP - 336

EP - 342

JO - Breast

JF - Breast

SN - 0960-9776

IS - 3

ER -